Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Herceptin and the heart--a molecular modifier of cardiac failure.

× No keyword cloud information.

34 in total

1. Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.

Authors: Michael F Press; Guido Sauter; Marc Buyse; Leslie Bernstein; Roberta Guzman; Angela Santiago; Ivonne E Villalobos; Wolfgang Eiermann; Tadeusz Pienkowski; Miguel Martin; Nicholas Robert; John Crown; Valerie Bee; Henry Taupin; Kerry J Flom; Isabelle Tabah-Fisch; Giovanni Pauletti; Mary-Ann Lindsay; Alessandro Riva; Dennis J Slamon
Journal: J Clin Oncol Date: 2010-12-28 Impact factor: 44.544

2. Biological therapies: concepts and challenges.

Authors: Markus Müller
Journal: Wien Klin Wochenschr Date: 2006-09 Impact factor: 1.704

3. Can serial changes of diastolic dysfunction signal incremental risk of chemotherapy-induced heart failure missed by the timing of declining LV ejection fraction?

Authors: Ronald G Schwartz; Nicholas Venci
Journal: J Nucl Cardiol Date: 2015-07-24 Impact factor: 5.952

Review 9. Cardio-Oncology: A Focused Review of Anthracycline-, Human Epidermal Growth Factor Receptor 2 Inhibitor-, and Radiation-Induced Cardiotoxicity and Management.

Authors: Jean Domercant; Nichole Polin; Eiman Jahangir
Journal: Ochsner J Date: 2016

Review 10. Cardiac dysfunction induced by novel targeted anticancer therapy: an emerging issue.

Authors: Ming Hui Chen
Journal: Curr Cardiol Rep Date: 2009-05 Impact factor: 2.931

Herceptin and the heart--a molecular modifier of cardiac failure.

1. Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.

2. Biological therapies: concepts and challenges.

3. Can serial changes of diastolic dysfunction signal incremental risk of chemotherapy-induced heart failure missed by the timing of declining LV ejection fraction?

4. The Yale Fitness Intervention Trial in female cancer survivors: Cardiovascular and physiological outcomes.

5. Echocardiography signs of early cardiac impairment in patients with breast cancer and trastuzumab therapy.

Review 6. Systems biology approaches to adverse drug effects: the example of cardio-oncology.

7. Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab.

Review 8. Present state and future perspectives of using pluripotent stem cells in toxicology research.

Review 9. Cardio-Oncology: A Focused Review of Anthracycline-, Human Epidermal Growth Factor Receptor 2 Inhibitor-, and Radiation-Induced Cardiotoxicity and Management.

Review 10. Cardiac dysfunction induced by novel targeted anticancer therapy: an emerging issue.